Stock Track | Corcept Therapeutics Plunges 7.17% After-Hours on Q3 Revenue Miss

Stock Track11-05

Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 7.17% in after-hours trading on Tuesday following the release of its third-quarter earnings report. The significant drop came as the company's revenue fell short of analyst expectations, overshadowing a better-than-expected earnings per share (EPS) result.

For the third quarter, Corcept reported revenue of $207.638 million, representing a 13.75% increase from the same period last year. However, this figure missed analyst estimates, which ranged from $218.526 million to $223.8 million. The company's EPS came in at $0.16, surpassing the consensus estimate of $0.14, but still showing a substantial 60.98% decrease from the $0.41 per share reported in the same quarter of the previous year.

Despite the revenue miss, Corcept maintained a positive outlook for the full year, projecting annual revenue between $800 million and $850 million. The company also reported a net income of $19.668 million for the quarter. However, the market's focus on the revenue shortfall appears to be the primary driver behind the stock's after-hours decline, as investors reassess the company's growth trajectory in light of the mixed earnings report.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136659010?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136659010","market":"us","top_or_hot":-1,"title":"Stock Track | Corcept Therapeutics Plunges 7.17% After-Hours on Q3 Revenue Miss","media":"Stock Track","content":"<p>Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 7.17% in after-hours trading on Tuesday following the release of its third-quarter earnings report. The significant drop came as the company's revenue fell short of analyst expectations, overshadowing a better-than-expected earnings per share (EPS) result.</p>\n\n<p>For the third quarter, Corcept reported revenue of $207.638 million, representing a 13.75% increase from the same period last year. However, this figure missed analyst estimates, which ranged from $218.526 million to $223.8 million. The company's EPS came in at $0.16, surpassing the consensus estimate of $0.14, but still showing a substantial 60.98% decrease from the $0.41 per share reported in the same quarter of the previous year.</p>\n\n<p>Despite the revenue miss, Corcept maintained a positive outlook for the full year, projecting annual revenue between $800 million and $850 million. The company also reported a net income of $19.668 million for the quarter. However, the market's focus on the revenue shortfall appears to be the primary driver behind the stock's after-hours decline, as investors reassess the company's growth trajectory in light of the mixed earnings report.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Corcept Therapeutics Plunges 7.17% After-Hours on Q3 Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Corcept Therapeutics Plunges 7.17% After-Hours on Q3 Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 05:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 7.17% in after-hours trading on Tuesday following the release of its third-quarter earnings report. The significant drop came as the company's revenue fell short of analyst expectations, overshadowing a better-than-expected earnings per share (EPS) result.</p>\n\n<p>For the third quarter, Corcept reported revenue of $207.638 million, representing a 13.75% increase from the same period last year. However, this figure missed analyst estimates, which ranged from $218.526 million to $223.8 million. The company's EPS came in at $0.16, surpassing the consensus estimate of $0.14, but still showing a substantial 60.98% decrease from the $0.41 per share reported in the same quarter of the previous year.</p>\n\n<p>Despite the revenue miss, Corcept maintained a positive outlook for the full year, projecting annual revenue between $800 million and $850 million. The company also reported a net income of $19.668 million for the quarter. However, the market's focus on the revenue shortfall appears to be the primary driver behind the stock's after-hours decline, as investors reassess the company's growth trajectory in light of the mixed earnings report.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1136659010","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136659010","pubTimestamp":1762292202,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 7.17% in after-hours trading on Tuesday following the release of its third-quarter earnings report. The significant drop came as the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"个股追踪|Corcept Therapeutics盘后暴跌7.17%因Q3营收未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"Corcept Therapeutics (NASDAQ: CORT) saw its stock price plummet 7.17% in after-hours trading on Tuesday following the release of its third-quarter earnings report. The significant drop came as the company's revenue fell short of analyst expectations, overshadowing a better-than-expected earnings per share (EPS) result.\nFor the third quarter, Corcept reported revenue of $207.638 million, representing a 13.75% increase from the same period last year. However, this figure missed analyst estimates, which ranged from $218.526 million to $223.8 million. The company's EPS came in at $0.16, surpassing the consensus estimate of $0.14, but still showing a substantial 60.98% decrease from the $0.41 per share reported in the same quarter of the previous year.\nDespite the revenue miss, Corcept maintained a positive outlook for the full year, projecting annual revenue between $800 million and $850 million. The company also reported a net income of $19.668 million for the quarter. However, the market's focus on the revenue shortfall appears to be the primary driver behind the stock's after-hours decline, as investors reassess the company's growth trajectory in light of the mixed earnings report.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136659010","isCrawlerRequest":true}